TReatIng Urinary symptoms in Men in Primary Healthcare using non-pharmacological and non-surgical interventions (TRIUMPH) compared with usual care: study protocol for a cluster randomised controlled trial.
Cluster randomised controlled trial
International Prostate Symptom Score
Lower urinary tract symptoms
Primary care
TRIUMPH
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
02 Sep 2019
02 Sep 2019
Historique:
received:
10
07
2019
accepted:
10
08
2019
entrez:
4
9
2019
pubmed:
4
9
2019
medline:
18
2
2020
Statut:
epublish
Résumé
Lower urinary tract symptoms (LUTS) can relate to urinary storage or voiding. In men, the prevalence and severity of LUTS increases with age, with a significant impact on quality of life. The majority of men presenting with LUTS are managed by their general practitioner (GP) in the first instance, with conservative therapies recommended as the initial treatment. However, the provision of conservative therapies in primary care is variable and can be time and resource limited. GPs require practical resources to enhance patient engagement with such interventions. TRIUMPH aims to determine whether a standardised and manualised care intervention delivered in primary care achieves superior symptomatic outcome for LUTS versus usual care. TRIUMPH is a two-arm, cluster randomised controlled trial (RCT) being conducted in 30 National Health Service (NHS) general practices in England. The TRIUMPH intervention comprises a standardised LUTS advice booklet developed for the trial with patient and healthcare professional (HCP) consultation. The booklet is delivered to patients by nurses/healthcare assistants following assessment of their urinary symptoms. Patients are directed to relevant sections of the booklet, providing the manualised element of the intervention. To encourage adherence, HCPs provide follow-up contacts over 12 weeks. Practices are randomised 1:1 to either deliver the TRIUMPH intervention or a usual care pathway. The patient-reported International Prostate Symptom Score (IPSS) at 12 months post consent is the primary outcome. Secondary outcomes include cost-effectiveness, patient-reported outcomes on LUTS, quality of life, and patient and HCP acceptability and experience of the intervention. Primary analyses will be conducted on an intention-to-treat basis. It is unclear whether conservative therapies for male LUTS are effectively delivered in primary care using current approaches. This can lead to men being inappropriately referred to secondary care or experiencing persistent symptoms. Primary care, therefore, holds the key to effective treatment for these men. The TRIUMPH intervention, through its standardised and manualised approach, has been developed to support GP practices in delivering effective conservative care. This pragmatic, cluster RCT should provide robust evidence in a primary-care setting to inform future guidelines. ISCRTN registry, ID: ISRCTN11669964 . Registered on 12 April 2018.
Sections du résumé
BACKGROUND
BACKGROUND
Lower urinary tract symptoms (LUTS) can relate to urinary storage or voiding. In men, the prevalence and severity of LUTS increases with age, with a significant impact on quality of life. The majority of men presenting with LUTS are managed by their general practitioner (GP) in the first instance, with conservative therapies recommended as the initial treatment. However, the provision of conservative therapies in primary care is variable and can be time and resource limited. GPs require practical resources to enhance patient engagement with such interventions. TRIUMPH aims to determine whether a standardised and manualised care intervention delivered in primary care achieves superior symptomatic outcome for LUTS versus usual care.
METHODS/DESIGN
METHODS
TRIUMPH is a two-arm, cluster randomised controlled trial (RCT) being conducted in 30 National Health Service (NHS) general practices in England. The TRIUMPH intervention comprises a standardised LUTS advice booklet developed for the trial with patient and healthcare professional (HCP) consultation. The booklet is delivered to patients by nurses/healthcare assistants following assessment of their urinary symptoms. Patients are directed to relevant sections of the booklet, providing the manualised element of the intervention. To encourage adherence, HCPs provide follow-up contacts over 12 weeks. Practices are randomised 1:1 to either deliver the TRIUMPH intervention or a usual care pathway. The patient-reported International Prostate Symptom Score (IPSS) at 12 months post consent is the primary outcome. Secondary outcomes include cost-effectiveness, patient-reported outcomes on LUTS, quality of life, and patient and HCP acceptability and experience of the intervention. Primary analyses will be conducted on an intention-to-treat basis.
DISCUSSION
CONCLUSIONS
It is unclear whether conservative therapies for male LUTS are effectively delivered in primary care using current approaches. This can lead to men being inappropriately referred to secondary care or experiencing persistent symptoms. Primary care, therefore, holds the key to effective treatment for these men. The TRIUMPH intervention, through its standardised and manualised approach, has been developed to support GP practices in delivering effective conservative care. This pragmatic, cluster RCT should provide robust evidence in a primary-care setting to inform future guidelines.
TRIAL REGISTRATION
BACKGROUND
ISCRTN registry, ID: ISRCTN11669964 . Registered on 12 April 2018.
Identifiants
pubmed: 31477160
doi: 10.1186/s13063-019-3648-1
pii: 10.1186/s13063-019-3648-1
pmc: PMC6720870
doi:
Types de publication
Clinical Trial Protocol
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
546Subventions
Organisme : Department of Health
ID : HTA/16/90/03
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Health Technology Assessment Programme
ID : 16/90/03
Références
Eur Urol. 1999 Apr;35(4):277-84
pubmed: 10087388
Eur Urol. 1999;36 Suppl 3:33-9
pubmed: 10559629
Clin Trials. 2005;2(2):99-107
pubmed: 16279131
BMJ. 2007 Jan 6;334(7583):25
pubmed: 17118949
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
BJU Int. 2009 Oct;104(8):1104-8
pubmed: 19485993
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):269-81
pubmed: 20545592
J Urol. 2013 Mar;189(3):987-92
pubmed: 23017510
Eur Urol. 2013 Jul;64(1):118-40
pubmed: 23541338
Eur Urol. 2015 Jun;67(6):1099-1109
pubmed: 25613154
Cochrane Database Syst Rev. 2015 Dec 02;(12):CD003505
pubmed: 26630349
Trials. 2015 Dec 10;16:567
pubmed: 26651344
Neurourol Urodyn. 2019 Jan;38(1):320-329
pubmed: 30311686
Eur Urol Focus. 2019 May;5(3):340-350
pubmed: 31047905
Urology. 1995 Jun;45(6):962-71
pubmed: 7539561